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of EpidemiB A C K G R O U N D Ischemic heart disease (IHD) is the leading cause of death worldwide. The Global
Burden of Diseases, Injuries and Risk Factors (GBD) 2010 Study estimated IHD mortality and disability
burden for 21 world regions for the years 1990 to 2010.
M E T H O D S Data sources for GBD IHD epidemiology estimates were mortality surveillance, verbal
autopsy, and vital registration data (for IHD mortality) and systematic review of IHD epidemiology
literature published from 1980 to 2008 (for nonfatal IHD outcomes). An estimation and validation process
led to an ensemble model of IHD mortality by country for all 21 world regions, adjusted for country-level
covariates. Disease models were developed for the nonfatal sequelae of IHD: myocardial infarction,
stable angina pectoris, and ischemic heart failure.
R E S U LT S Country-level covariates including metabolic and nutritional risk factors, education, war,
and annual income per capita contributed to the ensemble model for the analysis of IHD death. In the
acute myocardial infarction model, inclusion of troponin in the diagnostic criteria of studies published
after the year 2000 was associated with a 50% higher incidence. Self-reported diagnosis of angina
signiﬁcantly overestimated stable angina prevalence compared with “deﬁnite” angina elicited by the
Rose angina questionnaire. For 2010, Eastern Europe and Central Asia had the highest rates of IHD death
and the Asia Paciﬁc High-Income, East Asia, Latin American Andean, and Sub-Saharan Africa regions had
the lowest.
C O N C L U S I O N S Global and regional IHD epidemiology estimates are needed for estimating the
worldwide burden of IHD. Using descriptive meta-analysis tools, the GBD 2010 standardized and pooled
international data by adjusting for region-level mortality and risk factor data, as well as study-level
diagnostic method. Analyses maximized internal consistency, generalizability, and adjustment for
known sources of bias. The GBD IHD analysis, nonetheless, highlights the need for improved IHD
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Table 1. GBD cause mapping for the International
Classiﬁcation of Diseases (Revision 10, Revision 9, and Revision
9-BTL)
GBD Name ICD-10 ICD-9 ICD-9-BTL
Ischemic heart disease I20eI25 410e414 B27
GBD, Global Burden of Diseases Study.
Table 2. Site-years by decade and source type of IHD
mortality data
Source Type 1980e1989 1990e1999 2000e2011
Surveillance 0 27 24
Verbal autopsy 14 14 42
Vital registration 802 957 945
IHD, ischemic heart disease.
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332Ischemic heart disease (IHD) is the world’s
leading cause of death [1]. Large-scale IHD treat-
ment and prevention programs require accurate
burden of disease assessment at the regional level.
The Global Burden of Disease (GBD) Study was
commissioned by World Bank in 1991 (GBD
1990) [2,3] as an effort to provide summary measures
of mortality and disability/morbidity for 8 world
regions using standard measures across diseases,
including cardiovascular disease [4,5]. The GBD
2004 estimated burden for IHD and other cardiovas-
cular diseases in 14 regions [6]. Acute myocardial
infarction (AMI), stable angina, and heart failure
after AMI were estimated separately and then aggre-
gated to calculate total burden of IHD [6].
The GBD 2010 study aimed to estimate the
burden of cardiovascular disease in greater detail
using more primary data, and new methods were
developed for IHD burden estimation. Incidence
and prevalence of IHD sequelae were informed
primarily by regional IHD death rates. Estimating
regional IHD mortality was complicated by the
need to reallocate IHD deaths erroneously assigned
to ill-deﬁned cardiovascular causes [7]. A systematic
review of IHD incidence, prevalence, case-fatality,
and mortality studies published from 1980 to
2008 added additional information, but the review
also identiﬁed analytic challenges: Methods for
measuring IHD cases varied between studies,
regions, and time periods; and limited published
data were available for low- and middle-income
regions [8]. GBD 2010 sought to make country-
level estimates for the years 1990, 2005, and 2010
and to generate quantitative measures of uncertainty
for incidence, prevalence, case-fatality, mortality, and
other measures of burden. In this paper, we describe
the analytic approach and present global IHD epide-
miology estimates for 2010 in 21 world regions
(country and region list, Supplemental Table 1).
METHODS
Overview. The epidemiologic components of IHD
burden are IHD death and morbidity from AMI,
stable angina, and ischemic heart failure [8]. IHD
was 1 of 291 GBD major causes of death most often
categorized into International Classiﬁcation of
Diseases (ICD)-9 codes 410 to 414 and ICD-10
codes I20 to I25 (Table 1). IHD mortality was
analyzed using a standard cause of death ensemble
model (CODEm) algorithm [9]. Nonfatal IHD
burden was captured by estimating the prevalence of
AMI, stable angina, and ischemic heart failure.Nonfatal AMI, stable angina, and heart failure
envelope data were analyzed using DisMod-MR,
a meta-regression Bayesian modeling tool (Disease
Model, Meta-Regression, Institute for Health
Metrics and Evaluation, Seattle, WA, USA)
[10,11]. Prevalence of heart failure and proportion
of heart failure of ischemic origin were estimated
separately and were used to estimate prevalence of
ischemic heart failure.
IHD mortality data. We aggregated cause-speciﬁc
mortality data in a central database. Mortality data
were gathered from vital registration, verbal autopsy,
surveillance systems, survey/census, or police
reports. Starting with raw cause-of-death data,
comparability was enhanced by mapping across
various ICD versions (Table 1). We enhanced
verbal autopsy data by different methods and used
these in the analysis with other sources of data
[12e17]. Table 2 shows the number of data points
by type of source (vital registration, verbal autopsy,
and surveillance system) and by decade.
A key element of the analysis of cause-of-death
data was to take the raw cause-of-death data and
enhance comparability by mapping across various
revisions and national variants of the ICD and to
process garbage codes [7,18]. Garbage codes are
the deaths that have been coded to an intermediate,
immediate, or ill-deﬁned cause and must instead be
attributed to the underlying causes. Supplemental
Table 2 presents total increase and percent increase
by each garbage code as well as proportion of each
garbage code assigned to IHD in our ICD-10
data. Overall IHD death was increased about
21.5% after redistribution. Half of this increase
originated from reallocation of deaths coded to
senility (ICD-10 R54), hypertension (I10), athero-
sclerosis (I70), and all cardiac conduction disorders
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333to IHD (I44,I45). About 77% of heart failure
deaths were assigned to IHD death globally
(Supplemental Table 2). Deaths coded to heart fail-
uredan intermediate cause of death under ICD
rulesdwere redistributed to 17 causes including
IHD [19]. The proportion of deaths originally
coded as heart failure and moved to IHD was esti-
mated by modeling the etiologies of heart failure
[19]. Detailed methods for garbage code redistribu-
tion have been published elsewhere [7].
IHD cause of death model covariates. Several cova-
riates were used as candidate covariates to inform
estimation for the country-years without data. The
units of analysis were country, year, age, and sex.
Covariates were chosen based on a signiﬁcant
association with IHD death at the individual level
and an expected effect at the ecological level
(Table 3). The assumed direction of effect was
based on disease pathophysiology and the possible
effect of the covariate at individual and populationTable 3. Country-level covariates, acceptable direction of effect, n
mortality in ensemble method
Covariate Level
Men
CF*
Cumulative cigarette consumption, mean 5-year
per capita cigarette consumption [48]
1 89
Diabetes prevalence [46] 1 47
Mean body mass index, kg/m2 [49] 1 73
Mean systolic blood pressure, mm Hg 1 50
Mean serum cholesterol, mmol/l 1 47
Prevalence of smoking, self-reported active
smoking status [48]
1 87
Alcohol consumption, liters per capita [50] 2 74
Animal fat consumption, kcal per capita 2 62
Health system access, unitless 2 0
Fruit consumption, kcal per capita [51] 2 0
PUFA3 consumption, kcal per capita 2 90
Vegetables consumption, kcal per capita [51] 2 30
Milk consumption, kcal per capita [52] 2 0
Nut and seed consumption, kcal per capita [53] 2 19
Disaster death, rate per 1,000 person-years [54] 3 0
Education, years per capita [34,37] 3 0
Lag country income, US$ per capita [34,37] 3 16
PUFA6 consumption, kcal per capita 3 0
Population elevation, % of population dwelling at
>1,500 m [55]
3 67
Legume and pulses consumption, kcal per capita
[56]
3 27
Red meat consumption, kcal per capita [57,58] 3 31
War death, rate per 1,000 person-years [59] 3 0
Whole grain consumption, kcal per capita 3 0
IHD, ischemic heart disease; PUFA, polyunsaturated fatty acid.
* Logit of cause fraction (CF) expressed as a dependent variable in the model.level derived from the past literature. A separate arm
of the GBD 2010 estimated the level of covariates
for each country separately. Based on the nature and
sources of data, different sources such as country
surveys, censuses, international organizations such
as different U.N. agencies were analyzed. Different
methods were employed for this estimation
[19e22]. These separate reviews also catalogued
published association of risk factors such as Omega-
3 fatty acid consumption, cholesterol, and systolic
blood pressure with IHD [23].
Covariates were divided into 3 groups based on
strength of epidemiological evidence and presumed
proximity to IHD in the chain of causation. Level 1
covariates were those for which there was strong
evidence of a biologically plausible association with
IHD: diabetes mellitus prevalence, smoking and
cigarette consumption, and mean body mass index,
serum cholesterol, and systolic blood pressure
(Supplemental Table 3). Level 2 covariates includedumber of models, and ﬁnal contribution in estimating IHD
Women
Rate Contribution CF* Rate Contribution
139 30% 113 82 49%
0 30% 0 0 0%
0 35% 114 0 42%
82 25% 108 64 58%
57 55% 114 43 67%
120 61% 104 71 49%
122 11% 110 80 42%
106 10% 0 0 0%
46 0% 19 42 4%
109 0% 0 77 0%
84 18% 81 74 32%
102 16% 0 64 0%
128 0% 13 106 7%
101 0% 0 58 0%
0 0% 10 0 3%
41 0% 63 15 30%
53 10% 57 20 25%
20 0% 0 23 0%
65 22% 84 51 34%
64 0% 37 35 12%
66 6% 24 27 5%
70 0% 37 70 18%
0 0% 0 0 0%
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334covariates with some evidence of association but
with an indirect causal relationship, such as health
system access and alcohol, animal fat, polyunsatu-
rated fatty acid (PUFA) 3, fruits, vegetables, milk,
and nut consumption. Evidence for level 3 covari-
ates was observed in time-series or cross-sectional
studies: PUFA 6, legumes, red meat, and whole
grain consumption and country income per capita,
education, disaster, elevation, and war.
Two main families of IHD mortality models
were tested in the analysis: rate models (logarithm
of rate as dependent variable) and cause fraction
models [logit of cause fraction: lnðcf =1cf Þ]. In
the ﬁrst step, a mixed-effect regression for all
possible combinations of level 1 covariates was esti-
mated (with different number of covariates). All
models for which the direction was plausible and
the coefﬁcient association was signiﬁcant at the
p value <0.05 level were retained. Level 2 and 3
covariates were added to these models using
a forward technique checking all order-
independent combinations. All covariates had an
a priori deﬁned direction of effect on IHD except
alcohol consumption (both negative and positive
coefﬁcients would be acceptable) [24,25]. The
number of times a covariate was “picked up” by
the covariate selection process was the indicator of
independent ecological association between the
covariate and IHD death. We calculated and pre-
sented a ﬁnal contribution index for all covariates
by counting the number of times each covariate
was presented in the models contributed in
ﬁnal estimation by providing at least 1 of 1,000
draws.
Mortality analysis, CODEm model. CODEm
explores a large variety of possible models to esti-
mate trends in causes of death. Possible models
are identiﬁed using a covariate selection algorithm
that yields many plausible combinations of covari-
ates that are then run through 4 model classes.
The model classes include mixed-effects linear
models and spatiotemporal Gaussian process
regression models for cause fractions and death
rates. All models for each cause of death are then
assessed using out-of-sample predictive validity
and combined into an ensemble with optimal out-
of-sample predictive performance. Absolute
median relative error is the overall index of model
validity and is calculated by comparing the model
prediction with observed point of data. The
ensemble model produces uncertainty intervals for
each age-country-year for mortality. The 1,000draws from the Gaussian process regression step
provided uncertainty intervals to generate distribu-
tions of mortality in all age-country-year groups.
IHD out-of-sample predictive validity of component
models. The ensemble modeling strategy assessed
the performance of various component models.
We formally evaluated the ability of each of these
models to make accurate predictions by creating
20 train-test-test splits. For each of these datasets,
we randomly assign 70% of the data to the train
set, 15% to the ﬁrst test dataset, and the last 15% to
the second test dataset. For each train dataset,
we re-estimated each of the proposed models
including both the mixed-effects and the spatial-
temporal models. The test data were not included
in the model estimation; therefore, the performance
of each model was evaluated out-of-sample. Out-of-
sample predictions for the test set are a fair evalu-
ation of how each model will perform in predicting
IHD mortality where the data are sparse or missing.
Predictive validity was evaluated using 3 metrics.
First, we evaluated how well each model predicted
age-speciﬁc death rates using the root mean squared
error (RMSE) of the log of the death rate. Second,
we also wanted models that predict accurate trends.
To achieve this, for the test data, we computed the
log death rate in year t minus the log death rate
in year t-1. We also computed similar metric for
the prediction. We then counted the percentage of
the time that the model predicts the same trend as
the test data and proportion of the data in the test
set included in the 95% prediction interval of the
component model estimation. The prediction
interval was based both on the uncertainty in the
predicted death rate due to the models and the
data variance for each observation.
IHD corrected cause fractions based on the
mortality envelope (CODCorrect process). In order
to take advantage of using all cardiovascular death
data and to produce a more accurate estimate of
IHD deaths over time, we modeled death at
different cause levels. Different levels of analysis
for cardiovascular diseases were presented in Box
1. We corrected all cardiovascular mortality such
that the sum of all cause-speciﬁc deaths equals the
all-cause mortality “envelope.” In addition, mortality
rate estimations from cardiovascular causes (rheu-
matic heart disease, IHD, cerebrovascular disease,
and other cardiovascular diseases) were rescaled so
that sum of deaths equals all-cardiovascular death.
Estimating morbidity of IHD. Nonfatal IHD
sequelae prevalence and incidence were estimated
BOX 1. Different levels of causes of death (related
to cardiovascular causes) applied in CODCorrect
process in Global Burden of Diseases Study 2010.
Level 1: All-cause mortality (envelope)
Level 2: B.2. Cardiovascular and circulatory
diseases
Level 3: B.2.1. Rheumatic heart disease
Level 3: B.2.2. Ischemic heart disease
Level 3: B.2.3. Cerebrovascular disease
Level 4: B.2.3.1. Ischemic stroke
Level 4: B.2.3.2. Hemorrhagic and other nonische-
mic stroke
Level 3: B.2.4. Hypertensive heart disease
Level 3: B.2.5. Cardiomyopathy and myocarditis
Level 3: B.2.6. Atrial ﬁbrillation and ﬂutter
Level 3: B.2.7. Aortic aneurysm
Level 3: B.2.8. Peripheral vascular disease
Level 3: B.2.9. Endocarditis
Level 3: B.2.10. Other cardiovascular and circula-
tory diseases
G L O B A L H E A R T , V O L . 7 , N O . 4 , 2 0 1 2 Forouzanfar et al.
D e c e m b e r 2 0 1 2 : 3 3 1 - 3 4 2
Methods for Estimating the Global Epidemiology of IHD in 2010
335using DisMod-MR software. DisMod-MR is
a meta-regression mathematical modeling tool for
modeling epidemiological measures of a disease
together. In a Bayesian approach, ﬁrst, uses all
parameters (prevalence, incidence, and case fatality)
in a grand model considering country, region, and
super-region effects to come up with a rough esti-
mate for each region, year, sex, and age. It uses
different study-level covariates (to represent study
differences such as diagnostic method or source of
data), and country-level covariates (such as health
system performance and standardized stroke
mortality rate). The ﬁrst step estimates are called
empirical priors. In the second step, the empirical
prior is updated with local data (region, year, sex,
and age) to produce posterior distribution of each
parameter. The core mathematical model of Dis-
Mod-MR is based on a compartmental model
including susceptible population, patients, death, in
addition to the rate of transition. A comprehensive
explanation for DisMod-MR has been published in
an appendix [19] to GBD capstone papers in the
Lancet and in a separate paper [10]. Speciﬁc
modeling strategies and assumptions applied in
DisMod-MR modeling were summarized in
Supplemental Box 1.
AMI model. DisMod-MR [10,11,19] was used to
estimate the total number of patients living with
AMI. An AMI was assumed to cause symptoms up
to 28 days. The standard time frame for case fatalitywas 28 days because it was the interval deﬁned by
the MONICA (Multinational Monitoring of
Trends and Determinants in Cardiovascular
Disease) study (the highest quality case fatality data
with the most years covered), but 30-day case
fatality data were also analyzed. Because of the
limitations of population-based survey measures of
old MI prevalence (i.e., self-report of prior MI or Q
waves on resting electrocardiogram) [8], 2 types of
data were used in the AMI model: AMI incidence;
and AMI 28-day case fatality. For papers identiﬁed
in a systematic review of IHD epidemiology, data
on AMI epidemiology, years of observation, nation
or region, age, sex, diagnostic deﬁnition, and use of
troponin enzyme in AMI diagnosis were abstracted
[8]. The GBD deﬁnition of AMI was based on the
2007 World Health Organization (WHO) diag-
nostic deﬁnition [8,26]. Detection of positive
troponin, a biomarker of myocardial injury, is a key
component of the WHO category A deﬁnition, but
troponin measures were not commonly used for
AMI diagnosis in high-income studies until around
the year 2000. To this day, troponins are still not
widely used in many low- and middle-income
regions. Therefore, the WHO 2007 category B
AMI deﬁnitiondincluding cases lacking cardiac
biomarker measurementdwas also employed. In
the analysis, a study-level variable categorized AMI
incidence data as reporting of troponin measure-
ment or not and assumed all studies published prior
to 2000 did not measure troponin.
Twenty-eighteday case fatality was converted to
a rate (hazard) by the formula:
excess mortality rate ¼ ln

1 28 day case f atality
ð28=365Þ
IHD age-standardized death rate was used as
a country-level covariate in DisMod-MR to inform
prevalence multiplied by excess mortality. This
allowed DisMod-MR to adjust the level of incidence
and excess mortality according to regional MI
mortality. We estimated proportion of MI mortality
in IHD mortality, MI/IHD mortality ratio, at the
region, age, and sex level from the cause of death
database (vital registration data with ICD-9 and
ICD-10 codes in detail). The ratio of MI/IHD
mortality was applied to IHD death to estimate MI
mortality rate in DisMod-MR. The MI/IHD
mortality ratio was particularly low inEastern Europe
and was particularly high in the Sub-Saharan Africa
regions (Supplemental Box 2). Because we used the
IHD death rate as a country-level covariate, we did
Forouzanfar et al. G L O B A L H E A R T , V O L . 7 , N O . 4 , 2 0 1 2
Methods for Estimating the Global Epidemiology of IHD in 2010
D e c e m b e r 2 0 1 2 : 3 3 1 - 3 4 2
336not use the additional covariates that were included in
the production of these death rates during the
CODEm process (i.e., smoking, mean serum choles-
terol, systolic blood pressure, nutritional factors,
income, and health system access).
Angina pectoris. Most of the studies of angina pec-
toris included from the GBD systematic review
were population-based surveys that assessed angina
prevalence using the Rose angina questionnaire,
self-reported physician’s diagnosis of angina, or
more rarely physician-reported diagnosis or self-
reported use of antianginal medications [8]. We
found at least 1 point of prevalence data for
90 countries and 18 GBD regions. Incidence data
were found only for the United States, Finland, and
South Africa. We also used case-fatality data in
terms of standardized mortality ratio and relative
risk of mortality from angina natural history studies
to inform the model estimation [8]. Study-level
variables categorized method of diagnosing angina;
Rose questionnaire deﬁnite angina was set as the
standard method. Prevalence of stable angina from
2 surveysdthe WHS (World Health Study) and
MEPS (Medical Expenditure Panel Survey) [27]d
were used to informed age distribution and level of
stable angina in regions. Separate variables catego-
rized estimates based on the diagnostic deﬁnition:
Rose “deﬁnite” angina (our standard deﬁnition);
reporting Rose “probable” angina; or self-reported
history of angina. For DisMod-MR, IHD
mortality rate was used as a country-level covariate,
precluding use of covariates used in cause-of-death
estimation.
Ischemic heart failure. The ﬁrst step toward esti-
mating the burden of ischemic heart failure was to
estimate the total heart failure envelope. Data
were derived from the IHD systematic review or
from hospital discharge data for 24 countries [8].
For the hospital discharge data, the U.S. State
Inpatient Database was used to calculate a correc-
tion factor for heart failure using uniquely identiﬁ-
able individuals. This correction factor adjusted for
the fact that 1 person may be hospitalized in
multiple admissions in the database. To calculate
the correction factor, we tallied the number of all
patient records with heart failure and divided it by
the number of unique patients in the dataset by age
and sex. We then applied this correction factor to
the other hospital datasets without patient identi-
ﬁers by extracting all heart failure records and
dividing by the correction factor. The correction
factor values ranged from 1.12 to 1.76 depending on
patient age and sex.Because some prevalence and case-fatality data
were reported for more severe cases (New York
Heart Association class III), we deﬁned a study level
covariate to adjust for severity. We included age-
standardized death rate due to cardiomyopathy
(ICD-9 425 or ICD-10 I42) as a country-level
covariate. Average body mass index (over age
20 years) was included based on review of the liter-
ature [28]. We did not include other risk factors for
heart failure such as hypertension and smoking
because their direction was not plausible in Dis-
Mod-MR models (Supplemental Box 1).
Once the heart failure envelope was estimated, the
second step was to estimate the proportion of heart
failure cases attributable to IHD [29]. The distribu-
tion of 7 major heart failure causes identiﬁed among
heart failure patients was estimated from the system-
atic review and hospital records at the individual level
from the United States, Canada, Brazil, andMexico:
IHD; hypertensive heart disease; Chagas disease;
non-Chagas cardiomyopathies; cardiopulmonary
disease; valvular heart disease; and category of other
remaining etiologies. To produce the etiologic frac-
tion for the major etiology groups, we applied a hier-
archical model using super-region, region, and
country random effects on the proportion of heart
failure by DisMod-MR. Country-level covariates,
when applicable, informed prediction for countries
without data. By applying the etiologic fraction for
each cause to the heart failure prevalence on an
age- and region-speciﬁc basis, the prevalence of
ischemic heart failure was estimated [19].
Statistics. Uncertainty intervals were reported based
on 2.5 and 97.5 percentiles of the posterior distribu-
tion of the parameter in 1,000 draws followed
through different steps of the analysis but were
not reported here. The p values of the ensemble
model were estimated in a 1- or 2-sided basis if
the posterior distribution includes the null differ-
ence or zero difference. Incidence and mortality
rates and prevalence proportions were age stan-
dardized using the direct method and the WHO
reference population [30]. Results for 2010 were
reported by GBD region; countries composing each
region are listed in Supplemental Table 1.
R E SU L T S
IHD mortality. Smoking indicators, cholesterol, and
mean systolic blood pressure contributed signiﬁ-
cantly to the IHD mortality model (Table 3).
Alcohol was selected most often from level 2,
perhaps because either direction of effect was
Table 4. Age-standardized IHD mortality rate per 1,000
persons, age ‡30 years, 2010
Region Women Men Total
Asia Paciﬁc, High Income 0.5 0.8 0.6
Asia, Central 3.9 6.9 5.2
Asia, East 0.9 1.4 1.2
Asia, South 1.8 2.9 2.3
Asia, Southeast 1.1 1.9 1.5
Australasia 1.1 1.6 1.4
Caribbean 1.9 2.5 2.2
Europe, Central 2.0 3.5 2.7
Europe, Eastern 4.3 7.7 5.7
Europe, Western 1.0 1.7 1.3
Latin America, Andean 0.9 1.2 1.0
Latin America, Central 1.3 2.0 1.6
Latin America, Southern 1.1 1.9 1.5
Latin America, Tropical 1.3 2.0 1.7
North Africa/Middle East 2.0 3.1 2.5
North America, High Income 1.5 2.2 1.8
Oceania 1.6 2.1 1.9
Sub-Saharan Africa, Central 1.4 1.9 1.6
Sub-Saharan Africa, East 0.8 1.0 0.9
Sub-Saharan Africa, Southern 0.8 1.3 1.0
Sub-Saharan Africa, West 1.0 1.0 1.0
IHD, ischemic heart disease.
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337accepted. Among level 2 covariates, animal fat, fruit,
and vegetable consumption were picked up more
often than PUFA 3 consumption. But in terms of
informing ﬁnal estimation, PUFA 3 and vegetable
consumption contributed more signiﬁcantly than
other level 2 covariates. Health system access was
picked up moderately. All nutritional and socio-
economic factors were signiﬁcantly correlated with
IHD death. Body mass index and diabetes preva-
lence from level 1 and disaster deaths and whole
grain consumption from level 3 were not signiﬁ-
cantly correlated with IHD death.
In ﬁnal IHD mortality ensemble estimate, body
mass index, systolic blood pressure, cholesterol,
and smoking contributed signiﬁcantly. Contextual
covariates such as country income, education, and
war also contributed substantially to the IHD death
ensemble model, especially in women. Overall, only
cause fraction models (linear and space-time
models) were selected by out-of-sample, external
validity criteria for ﬁnal estimation. Rate models
did not have comparable external validity.
In total, there were 164 cause fraction models
selected for men and 210 for women. In addition,
there were 232 rate models selected for men and
141 for women. The ﬁnal ensemble models selected
for men and women performed well in terms of
RMSE of the log of the death rate, proportion
with correct trend, and percent of data covered by
the model’s 95% conﬁdence interval (CI) (Supple-
mental Table 4). The average out-of-sample
RMSE was lower (0.65 for women and 0.58 for
men) in the ensemble model compared with the
best individual model (0.66 for women and 0.59
for men). In addition, the data coverage in the
ensemble model was superior. Estimated deaths
due to IHD and other individual causes were
rescaled to the total mortality envelope. Supple-
mental Figure 1 illustrates deaths due to IHD and
other individual causes before and after this process
(CODCorrect step).
IHD death rate was age standardized for
ages 30 years and all GBD regions for 2010
(Table 4). IHD death rate was highest in Eastern
Europe and Central Asia. Following these, Central
Europe and North Africa, Middle East regions had
the highest rates of IHD death. The 4 Sub-Saharan
Africa regions, Latin America Andean, and East
Asia had among the lowest IHD death rates.
MI incidence. After adjusting for IHD mortality
rate as well as super-region and region effects,
there was not considerable heterogeneity between
countries in each region (Supplemental Fig. 2).IHD mortality was a positive and signiﬁcant co-
variate (p value <0.005). Incidence of MI was
overall about 2.0 (95% CI: 1.85 to 2.26) times
higher in men than in women. Analysis of covariate
coefﬁcients suggested that estimated AMI incidence
is 51% (95% CI: 46% to 56%) lower when positive
troponin was not used to diagnose AMI. Incidence
was 13% lower (95% CI: 5% to 20%) when only
non-fatal MI was reported and 26% lower (95% CI:
16% to 34%) when only ﬁrst-ever MI was reported
(differences signiﬁcant at 0.001 level). The Dis-
Mod-MR model output for Western Europe
demonstrates how closely the ﬁnal estimate follows
the data (adjusted for study level covariates) (Online
Fig. 3). In general, AMI incidence in 2010 had
a regional distribution similar to IHD death, though
AMI incidence estimated for Sub-Saharan Africa
was no longer among the lowest (Table 5). There
was a smaller ratio of MI incidence to IHD death in
Asia Paciﬁc High Income compared with higher
IHD risk regions such as Eastern Europe, Central
Asia, and North Africa, Middle East. The impli-
cation is that patients die of AMI in high IHD
mortality rate countries and more patients die due to
the chronic sequelae of IHD in low IHD mortality
regions such as Asia Paciﬁc High Income.
In a preliminary model, AMI 28-day case fatality
was higher in high IHD mortality regions and
Table 6. Twenty-eighteday case-fatality proportion of MI in
age ‡45 years, 2010
Region Women Men
Asia Paciﬁc, High Income 0.27 0.29
Asia, Central 0.64 0.75
Asia, East 0.44 0.42
Asia, South 0.51 0.52
Asia, Southeast 0.42 0.46
Australasia 0.34 0.36
Caribbean 0.51 0.52
Europe, Central 0.51 0.59
Europe, Eastern 0.63 0.73
Europe, Western 0.35 0.39
Latin America, Andean 0.38 0.39
Latin America, Central 0.46 0.49
Latin America, Southern 0.38 0.44
Latin America, Tropical 0.47 0.48
North Africa/Middle East 0.54 0.54
North America, High Income 0.37 0.39
Oceania 0.51 0.53
Sub-Saharan Africa, Central 0.55 0.57
Sub-Saharan Africa, East 0.46 0.43
Sub-Saharan Africa, Southern 0.42 0.45
Sub-Saharan Africa, West 0.51 0.46
MI, myocardial infarction.
Table 7. Age-standardized prevalence proportion of stable
angina per 100 persons, age ‡30 years, 2010
Region Women Men Total
Asia Paciﬁc, High Income 2.5 3.3 2.9
Asia, Central 5.0 6.8 5.8
Asia, East 3.0 3.7 3.3
Asia, South 2.5 3.2 2.8
Asia, Southeast 2.6 3.3 3.0
Australasia 2.8 3.6 3.2
Caribbean 2.8 3.4 3.1
Europe, Central 3.3 4.5 3.8
Europe, Eastern 4.7 6.6 5.4
Europe, Western 2.8 3.8 3.2
Latin America, Andean 2.4 2.9 2.7
Latin America, Central 2.7 3.4 3.0
Latin America, Southern 2.3 3.3 2.8
Latin America, Tropical 4.0 5.1 4.5
North Africa/Middle East 3.7 4.6 4.1
North America, High Income 2.5 3.3 2.9
Oceania 2.8 4.1 3.4
Sub-Saharan Africa, Central 2.5 3.4 2.9
Sub-Saharan Africa, East 3.2 3.9 3.5
Sub-Saharan Africa, Southern 2.7 3.5 3.1
Sub-Saharan Africa, West 3.3 3.8 3.5
Table 5. Age-standardized incidence of MI per 1,000 persons,
age ‡30 years, 2010
Region Women Men Total
Asia Paciﬁc, High Income 1.08 2.21 1.61
Asia, Central 4.09 7.12 5.40
Asia, East 1.63 2.73 2.17
Asia, South 3.10 4.96 4.01
Asia, Southeast 2.16 3.54 2.80
Australasia 1.94 3.79 2.83
Caribbean 2.96 4.27 3.58
Europe, Central 2.91 5.45 4.04
Europe, Eastern 4.12 8.29 5.79
Europe, Western 1.84 3.90 2.81
Latin America, Andean 2.11 3.06 2.56
Latin America, Central 2.60 4.05 3.28
Latin America, Southern 1.96 3.97 2.86
Latin America, Tropical 2.45 4.20 3.25
North Africa/Middle East 3.43 5.35 4.36
North America, High Income 2.05 3.91 2.91
Oceania 2.55 3.96 3.20
Sub-Saharan Africa, Central 3.29 4.46 3.83
Sub-Saharan Africa, East 2.83 3.50 3.14
Sub-Saharan Africa, Southern 2.40 3.54 2.89
Sub-Saharan Africa, West 3.02 3.61 3.30
MI, myocardial infarction.
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338higher in women than in men (Supplemental
Fig. 4). But, after adjusting for IHD mortality
rate, 28-day case fatality was slightly higher in
men than in women (Table 6).
Angina prevalence. Overall, Rose deﬁnite stable
angina was more prevalent in men than in women
(1.13, 95% CI: 1.04 to 1.22) (Table 7, Supple-
mental Fig. 5). Other case deﬁnitions led to prev-
alence estimates higher than the main estimate:
“probable” angina by Rose questionnaire or using
other questionnaires: 12% higher (95% CI: 7% to
34%); self-report of stable angina diagnosis: 78%
higher (95% CI: 64% to 94%); and diagnosis re-
ported by the study physician: 37% higher (95% CI:
25% to 52%). Prevalence of angina was signiﬁcantly
correlated with the IHD standardized death rate.
WHS estimates for Sub-Saharan Africa nations
were very close to the main prevalence estimate for
Sub-Saharan Africa regions (relative prevalence:
0.96, not signiﬁcant at 0.05). WHS country survey
estimates were 21% higher than the main regional
prevalence estimates in other regions (relative
prevalence: 1.21; p value ¼ 0.05). Because of sparse
data on stable angina incidence, coefﬁcients for
predictors of angina incidence were unstable except
for a signiﬁcant correlation with IHD standardized
death rate (p value ¼ 0.02).Eastern Europe and Central Asia had the high-
est angina prevalence in 2010 (Supplemental
Fig. 6). For most regions, angina prevalence in
Table 9. Age-standardized prevalence proportion of ischemic
heart failure per 100 persons, age ‡30 years, 2010
Region Women Men Total
Asia Paciﬁc, High Income 0.18 0.29 0.23
Asia, Central 0.38 0.68 0.51
Asia, East 0.17 0.23 0.20
Asia, South 0.26 0.37 0.32
Asia, Southeast 0.29 0.34 0.31
Australasia 0.34 0.65 0.49
Caribbean 0.37 0.43 0.40
Europe, Central 0.44 0.61 0.52
Europe, Eastern 0.54 1.10 0.75
Europe, Western 0.47 0.84 0.64
Latin America, Andean 0.23 0.23 0.23
Latin America, Central 0.27 0.33 0.30
Latin America, Southern 0.52 0.77 0.63
Latin America, Tropical 0.33 0.41 0.37
North Africa/Middle East 0.64 0.58 0.61
North America, High Income 0.79 1.17 0.97
Oceania 0.90 1.03 0.96
Sub-Saharan Africa, Central 0.16 0.24 0.19
Sub-Saharan Africa, East 0.16 0.28 0.22
Sub-Saharan Africa, Southern 0.35 0.38 0.36
Sub-Saharan Africa, West 0.11 0.15 0.13
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339middle age (ages 20 to 40 years) was less than 4%.
Prevalence was estimated to decrease after age 80
years as incidence decreases, whereas excess
mortality still increased. Incidence of stable angina
was estimated to be more than 3 cases per 1,000
in Eastern Europe and Central Asia (Table 8).
Ischemic heart failure prevalence. The proportion
of the total heart failure prevalence envelope attrib-
uted to IHD was the highest in developed countries
besides Latin America and North Africa/Middle
East; this fraction was the smallest in Sub-Saharan
Africa (Supplemental Fig. 7). Table 9 lists esti-
mated prevalence of IHD heart failure by region
in 2010.
D I S CU S S I ON
IHD is a leading cause of death and disability
worldwide and estimating IHD epidemiology as
accurately as possible for all world regions is of
crucial importance. The GBD 2010 study
combined different sources of data and deﬁnitions
in order to estimate numbers of IHD deaths,
AMI incidence, and prevalence of stable angina
and ischemic heart failure for 21 world regions for
the years 1990 and 2010. For IHD mortality, we
demonstrated that an ensemble method approach
improved the external validity of results, capturedTable 8. Age-standardized incidence rate of stable angina
pectoris per 1,000 persons, age ‡30 years, 2010
Region Women Men Total
Asia Paciﬁc, High Income 2.26 2.87 2.56
Asia, Central 4.56 6.39 5.37
Asia, East 2.53 3.15 2.84
Asia, South 2.74 3.57 3.16
Asia, Southeast 2.26 2.85 2.54
Australasia 2.42 3.11 2.76
Caribbean 2.50 3.14 2.80
Europe, Central 2.99 4.01 3.46
Europe, Eastern 3.84 5.54 4.54
Europe, Western 2.28 3.06 2.65
Latin America, Andean 2.22 2.58 2.39
Latin America, Central 2.41 2.96 2.67
Latin America, Southern 2.11 3.02 2.53
Latin America, Tropical 3.12 4.08 3.57
North Africa/Middle East 3.40 4.27 3.83
North America, High Income 2.45 3.35 2.88
Oceania 2.48 3.88 3.15
Sub-Saharan Africa, Central 2.22 3.10 2.63
Sub-Saharan Africa, East 2.66 3.21 2.92
Sub-Saharan Africa, Southern 2.33 2.95 2.61
Sub-Saharan Africa, West 2.80 3.18 2.98local differences between countries, and revealed
hidden temporal trends by country. A novel soft-
ware program, DisMod-MR, was used to estimate
prevalence and incidence of AMI, angina, and
ischemic heart failure.
The backbone of nonfatal IHD burden estima-
tion was IHD death rates, estimated from regional
source data after reallocation of “garbage coded”
cardiovascular deaths to IHD. We employed
current knowledge on metabolic and nonmetabolic
factors to inform estimation for many countries
where no hard evidence was available. Out-of-
sample predictive validity conﬁrmed the generaliz-
ability of the results and demonstrated that an
ensemble method of regional IHD mortality rates
provides a more stable approach that minimizes
the effects of outlying data and improves the
external validity of the results. Country-level covari-
ates contributed in ensemble model were consistent
with the IHD risk factor literature [31]. The associ-
ation we found between education, income, and
IHD death has been observed in other studies
[32e37]. Associations between risk factors and
IHD were ecological and the strength of the associ-
ations may not be equal to what would be observed
at the level of the individual for risk factors such as
smoking, cholesterol, and blood pressure [38].
However, estimating the association between
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340protective factors or risk factors and IHD at the
country and single-year level is important for policy
making at the population level and may generate
hypotheses for individual level research [38].
Because of the unpredictable nature of some risk
factors such as country income, disaster, and war,
the most feasible approach to studying their
hazardous effect may be through ecological and
time series studies [38]. Evidence of independent
effects of contextual covariates such as education,
war, and income lends support to the hypothesis
that IHD originates not only from individual
behavior, but also at the societal level [39].
In recent years, a new “universal” deﬁnition ofAMI
was promoted, advocating for diagnosis based on
a troponin biomarker level at least 1 value above the
99th percentile of the upper reference limit in addition
to classic clinical symptoms and signs [40]. A study-
level “troponin use” variable addressed the challenge
ofMI incidence data that did not incorporate troponin
measures over time (troponins were not widely avail-
able until after about 1995) or space (troponin testing
is unavailable even today in many regions). Troponin
improves sensitivity without sacriﬁcing speciﬁcity of
MI [41,42]. Previous studies reported that troponin
improves the under detection of MI cases by approxi-
mately 40% to 70% [43]. Though not restricted to
comparing studies adhering strictly to the “old” and
“new” WHO AMI diagnostic deﬁnitions [44], our
estimate suggests that almost one-half of allAMI cases
are not detected when troponins are not used for diag-
nosis. All future studies estimating AMI incidence
trends will need to adjust for temporal and regional
differences in the use of troponins use and other
important diagnostic methods.
The analysis of stable angina prevalence adjusted
for use of different instruments, deﬁnitions, and
information sources. We found that on average,
studies reporting self-report of angina history (specif-
ically, positive response to the question “Has a doctor
told you of a diagnosis of angina?”) led to prevalence
estimates that were 78% higher (95% CI: 64% to
94%) than prevalence estimated using Rose question-
naire deﬁnite angina. This difference could be due to
physicians having access to more historical informa-
tion or poor sensitivity on the part of the Rose ques-
tionnaire. It is unknown whether cardiac stress
testing with or without coronary perfusion scanning
increases or decreases the rate of angina diagnosis,
or even if these tests are the appropriate gold stan-
dard for comparison with survey questionnaire-
based angina diagnosis [45]. Lacking a gold standard
for determining which instrument had more accuracyand reliability across populations, we chose Rose
deﬁnite angina over self-reported history as the stan-
dard because it was the conservative choice and
because the Rose questionnaire was used in the
WHS, leading to better global coverage.
The strengths of this analysis were that it was based
on comprehensive cause-of-death data covering all 21
regions and every year from 1990 to 2010, study-level
data from a large and validated systematic review of the
worldwide IHD epidemiology literature, andmethods
for achieving an internally consistent disease model of
IHD, estimating missing data, and adjusting measur-
able sources of bias. The GBD IHD estimation also
had limitations. Primarily,methods developed for esti-
mating missing data and adjusting for measurement
differences among source studies are no real substitute
for high-quality IHD surveillance data from every
GBD region, using standardized case deﬁnitions and
measurement methods. IHD risk factors are well
known at the individual level. For the ecological and
country levels, the effect may not be identical to those
effects at the individual level, whichmay produce difﬁ-
culties in interpretation. Some factors such as diabetes
prevalence and fasting blood glucose are known to be
important at the individual level [46], but formodeling
at the country level, these covariates showed minor
effects. We did not count the quality-of-life or
mortality impact of invasive procedures such as percu-
taneous coronary interventions or coronary artery
bypass graft surgery, nor did we count disability related
to unstable angina; most likely, this leads to burden
underestimation in high-income regions. The GBD
is not designed to ensure that risk factor exposures
precede disease outcomes, nor can past data be relied
on to predict future trends. For example, the current
covariates poorly explain the situation in Sub-
Saharan Africa where we estimated that IHD
mortality continues to be relatively rare, whereas prev-
alence of risk factors such as hypertension has
been rising [47].
CONC LU S I ONS
Health policy and research allocation decisions must
be made now, and global burden of disease esti-
mates are an important source of information for
decision makers. The GBD 2010 study aimed to
provide new IHD burden estimates for 2010 and
to improve on past estimates for 1990 by harnessing
state-of-the-art methods for analyzing the best
available mortality and morbidity data, ensuring
disease model internal consistency, and adjusting
for measurement bias. We found that IHD
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341mortality and morbidity in Western, high-income
regions was lower in 2010 than in the prior 2
decades, but it remains high in Eastern Europe,
Central Asia, North Africa, and the Middle East.
IHD appears to have remained relatively less preva-
lent in the East Asian and Sub-Saharan Africa
regions. IHD estimates are still limited by sparse
data in many low- and middle-income regions and
inconsistent measurement methods among studies
and regions. The mission of the GBD IHD expert
group was not only to provide estimates of IHD
burden worldwide, but also to present the state of
current knowledge of global cardiovascular diseaseepidemiology, and promote improved IHD surveil-
lance worldwide.
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